Overview

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

Status:
Completed
Trial end date:
2015-04-15
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer